N. Kurdil1, O. Ivashchenko2, B. Sheiman1, V. Andryushchenko3
1L.I. Medved’s Research Center of Preventive Toxicology, Food and Chemical Safety, Ministry of Health, Ukraine (State Enterprise), Kyiv, Ukraine
2Shupyk National University of Health Care of Ukraine, Kyiv, Ukraine
3CNE "Kyiv City Clinical Hospital of Emergency Medical Care", Kyiv, Ukraine
ABSTRACT. Introduction. In the conditions of the spread of powerful synthetic opioids, the traditionally recommended doses of Naloxone may be insufficient; instead, a significant increase in the dose of Naloxone leads to side effects, which in turn creates a threat to life.
Aim. Analysis of the results of own research and scientific information regarding the use of Naloxone in the treatment of synthetic opioids poisoning and the development of alternative antidotes.
Materials and Methods. The medical data of 174 patients treated with the diagnosis: "Acute narcotic poisoning" (ICD-10:Т40.0-Т40.3) were studied. Laboratory studies were carried out by the method of immunochromatographic analysis and chromatographymass spectrometry. Statistical data processing was performed using the IBM SPSS Statistics 29.0.0.0 program, using Spearman's rank correlation analysis (r), with p ≤ 0.05.
Results. Among patients who received Naloxone, the best dynamics according to the Glasgow coma scale at the 4th and 6th hours of observation were those who received 2-6 mg of Naloxone. A significant part of patients (76 cases, 43.68 %) required repeated administration of Naloxone due to the renarcotization, in such cases a direct correlation was established with the occurrence of undesirable clinical effects (r = 0.864, p = 0.05). A direct relationship between an increase in the dose of Naloxone and the development of arterial hypertension (r = 0.945, p = 0.01), convulsions (r = 0.887, p = 0.01), withdrawal and pain syndrome (r = 0.881, p = 0.01). In general, the occurrence of clinical effects was correlated with an increase in the dose of Naloxone (R2 = 0.92), however, the rank correlation analysis did not confirm the relationship between the dose of Naloxone and the development of pulmonary edema (r = 0.938, p > 0.05), cardiac arrhythmia (r= 0.598, p > 0.05), cardiac arrest (r= -0.146, p > 0.05).
Conclusions. The use of high doses of Naloxone does not solve the problem of prevention of opioid overdoses and their effective treatment. The development of new models of antidotes to opioids using сovalent Naloxone nanoparticles, serotonin 5-HT1A agonists, Fentanyl-binding Cyclodextrin scaffolds, specific vaccines, etc. is considered promising.
Keywords: opioids, antidotes, Naloxone, Fentanyl.
СПИСОК ВИКОРИСТАНИХ ДЖЕРЕЛ/REFERENCES
1. European Monitoring Center for Drugs and Drug Addiction (EMCDDA). European Drug Report 2021: Trends and Developments. URL:https://www.emcdda.europa.eu/publications/edr/trends-developments/2021_en.
2. Looking back on 25 years of annual reporting on the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, 2020. Electronic resource. Available online:https://www.emcdda.europa.eu/publications/brochures/25-years-annual-reporting_en. doi:10.2810/199193.
3. Wilson N, Kariisa M, Seth P, Smith H. 4th, Davis N.L. Drug and Opioid-Involved Overdose Deaths – United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297. doi:10.15585/mmwr.mm6911a4.
4. Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, Doe-Simkins M, Walley AY, Marshall BDL, Bratberg J, Green TC. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022 Mar; 7(3):e210-e218. doi:10.1016/S2468-2667(21)00304-2.
5. Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-Waters MM, Brasher PMA, Hau JP, Curran J, Hohl CM. Naloxone interventions in opioid overdoses: a systematic review protocol. Syst Rev. 2019 Jun 11;8(1):138. doi:10.1186/s13643-019-1048-y.
6. Beardsley PM, Zhang Y. Synthetic Opioids. HandbExpPharmacol. 2018;252:353-381.doi:10.1007/164_ 2018_ 149.
7. Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018 May 15;134(Pt A):121-132. doi:10.1016/j.neuropharm.2017.10.016.
8. Ross RB, Carlo DJ. Higher doses of Naloxone are needed in the synthetic opioid era. Subst. Abuse Treat. Prev. Policy. 2019. 14, 6. doi:10.1186/s13011-019-0195-4.
9. Carpenter J, Murray BP, Atti S, Moran TP, Yancey A, Morgan B. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl. J Med Toxicol. 2020 Jan;16(1):41-48. doi:10.1007/s13181-019-00735-w.
10. Abdelal R, Banerjee AR, Carlberg-Racich S, Cebollero C, Darwaza N, Kim C, Ito D, Epstein J. Real-world study of multiple naloxone administrations for opioid overdose reversal among emergency medical service providers. Subst Abus. 2022;43(1):1075-1084. doi:10.1080 /08897077.2022.2060433.
11. Strickland JC, Marks KR, Smith KE, Ellis JD, Hobelmann JG, Huhn AS. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose. Int J Drug Policy. 2022 Aug; 106:103751. doi:10.1016/j.drugpo.2022.103751.
12. Neale J, Kalk NJ, Parkin S, Brown C, Brandt L, Campbell ANC, Castillo F, Jones JD, Strang J, Comer SD. Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. J Subst Abuse Treat. 2020 Oct;117:108099. doi:10.1016/j.jsat.2020.108099.
13. Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Op in Drug Saf. 2015;14: 1137–1146. doi:10.1517/14740338.2015.1037274.
14. Abdelal R, Raja Banerjee A, Carlberg-Racich S, Darwaza N, Ito D, Shoaff J. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Epstein J. Harm Reduct J. 2022 May 20;19(1):49. doi:10.1186/s12954-022-00627-3.
15. Marco CA, Trautman W, Cook A, Mann D, Rasp J, Perkins O, Ballester M. Naloxone use among emergency department patients with opioid overdose. The Journal of Emergency Medicine. 2018;55(1):64–70. doi:10.1016/j.jemermed.2018.04.022.
16. Shafer SL. Carfentanil: a weapon of mass destruction. Can. J. Anaesth. 2019. 66, 351–355. doi:10.1007/s12630-019-01295-x.
17. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N. Engl. J. Med. 2017. 377, 391–394. doi:10.1056/NEJMsr1706626.
18. France CP, Ahern GP, Averick S, Disney A, Enright HA, et al. Countermeasures for Preventing and Treating Opioid Overdose. Clin Pharmacol Ther. 2021 Mar;109(3):578-590. doi:10.1002/cpt.2098.
Стаття надійшла до редакції 07.07.2023
The article was received by the editors 07.07.2023